Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

standby. We're about to begin. Good afternoon, everyone. Welcome to the Krenetics Pharmaceuticals fourth quarter and full year 2024 financial results conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question and answer session. You may register to ask a question at any time by pressing star 1 on your telephone. Also, today's call is being recorded, and with that, I'll turn things over to Gayathri Diwakar, Head of Investor Relations. Please go ahead, ma'am. Thank you, Operator. Good afternoon, everyone, and thank you for joining us to discuss the fourth quarter and full year 2024 results. Today on the call, we have Dr. Scott Struthers, Founder and Chief Executive Officer, Isabel Calafonos, Chief Commercial Officer, Dr. Dana Pizzuti, Chief Medical and Development Officer, Dr. Steve Betts, Founder and Chief Scientific Officer, and Mark Wilson, Chief Financial Officer. Also joining us for Q&A is Dr. Alan Krasner, Chief Endocrinologist. Please note there is a slide deck for today's presentation, which is in the Events and Presentations section of the Investors page on the Kinetics website. In addition, a press release was issued earlier today and is also available on the corporate website. Slide two. As a reminder, we'll be making forward-looking statements, and I invite you to learn more about the risks and uncertainties associated with these statements as disclosed in our SEC filing. Such forward-looking statements are not a guarantee of performance, and the company's actual results can differ materially from those stated or implied in such statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified in their entirety by t...